Inavir is a long-acting neuraminidase inhibitor with therapeutic efficacy after a single dosage. Inavir shows the same efficacy with a single dose as a five-day administration of oseltamivir, Daiichi Sankyo said.

As a new treatment option for influenza, Daiichi Sankyo is confident that Inavir will be an important alternative for treating influenza, both benefiting patients and contributing to society.

Daiichi Sankyo plans to supply 2 million units of the treatment (40mg) by the end of December 2010 and 4 million units (40mg) by the end of March 2011.